Table 1.
Demographics and perioperative variables.
| Variables | Non-Survival (N = 31) | Survival (N = 129) | p Value |
|---|---|---|---|
| Age, years | 55.7 (13.5) | 55.1 (11.8) | 0.815 |
| Male sex | 19 (61%) | 60 (47%) | 0.140 |
| Body mass index, kg/m2 | 19.9 (3.7) | 22.0 (3.7) | 0.007 * |
| ASA physical status | 0.285 | ||
| I | 5 (16%) | 37 (29%) | |
| II | 20 (65%) | 76 (59%) | |
| III | 6 (19%) | 16 (12%) | |
| Comorbidities | |||
| Hypertension | 7 (23%) | 37 (29%) | 0.495 |
| Diabetes mellitus | 2 (6%) | 18 (14%) | 0.369 |
| Prior chemotherapy | 24 (77%) | 81 (63%) | 0.124 |
| Preoperative PCI score | 19.4 (11.7) | 12.6 (10.9) | 0.004 * |
| Combined surgery | 20 (65%) | 78 (60%) | 0.678 |
| Operation time, min | 649.5 (191.3) | 593.2 (195.3) | 0.150 |
| Intraoperative input and output | |||
| Total fluid, mL | 7183 (2694) | 6900 (3168) | 0.647 |
| Colloid, mL | 952 (582) | 6032 (2960) | 0.425 |
| 20% Albumin, mL | 148 (190) | 111 (160) | 0.259 |
| Blood loss, mL | 1373 (978) | 1076 (1028) | 0.148 |
| Urine output, mL | 1040 (670) | 1104 (718) | 0.652 |
| pRBC, n | 1.9 (2.4) | 0.9 (1.5) | 0.039 * |
| Number of patients who received inotropic agents | |||
| Phenylephrine, n | 13 (42%) | 66 (51%) | 0.356 |
| Norepinephrine, n | 20 (65%) | 60 (47%) | 0.072 |
| Temperature | |||
| Prior to operation | 36.3 (0.5) | 36.2 (0.3) | 0.161 |
| Highest | 38.6 (0.6) | 38.5 (0.8) | 0.430 |
| At the end of operation | 36.3 (0.5) | 36.4 (0.6) | 0.621 |
| ICU admission, n | 30 (97%) | 112 (87%) | 0.202 |
| APACHE score | 16.4 (6.6) | 15.1 (6.8) | 0.346 |
| Types of cancer | 0.425 | ||
| Appendiceal cancer | 6 (19.4%) | 23 (17.8%) | |
| Ascending colon cancer | 7 (22.6%) | 21 (16.3%) | |
| Cecal cancer | 3 (9.7%) | 6 (4.7%) | |
| Descending colon cancer | 2 (6.5%) | 3 (2.3%) | |
| Peritoneal mesothelioma | 1 (3.2%) | 7 (5.4%) | |
| Rectal cancer | 5 (16.1%) | 19 (14.7%) | |
| Sigmoid cancer | 5 (16.1%) | 43 (33.3%) | |
| Transverse colon cancer | 2 (6.5%) | 7 (5.4%) | |
| Preoperative | |||
| NLR | 4.6 (4.4) | 2.2 (1.5) | 0.005 * |
| PLR | 243.3 (135.8) | 150.7 (84.8) | <0.001 * |
| MPV | 9.8 (1.1) | 9.5 (0.9) | 0.094 |
| Postoperative Day 2 | |||
| NLR | 21.6 (13.7) | 14.7 (9.2) | 0.014 * |
| PLR | 309.3 (208.6) | 207.0 (95.3) | 0.013 * |
| MPV | 10.6 (1.0) | 10.3 (0.8) | 0.153 |
| Postoperative Day 3 | |||
| NLR | 25.3 (19.4) | 14.8 (12.5) | 0.008 * |
| PLR | 358.2 (228.5) | 226.7 (107.3) | 0.004 * |
| MPV | 10.7 (0.9) | 10.2 (1.3) | 0.018 * |
| Postoperative Day 4 | |||
| NLR | 17.5 (12.0) | 10.9 (8.5) | 0.008 * |
| PLR | 385.3 (229.1) | 291.7 (166.0) | 0.043 * |
| MPV | 10.6 (0.9) | 10.2 (0.8) | 0.013 * |
| Postoperative Day 5 | |||
| NLR | 10.8 (5.5) | 7.6 (6.7) | 0.019 * |
| PLR | 373.2 (246.2) | 290.0 (167.5) | 0.094 * |
| MPV | 10.7 (0.9) | 10.1 (1.2) | 0.007 * |
Values are presented as mean (standard deviation) or number of patients (%). * p < 0.05. APACHE—Acute Physiology and Chronic Health Evaluation; ASA—American Society of Anesthesiologists; PCI—peritoneal cancer index; pRBC—packed red blood cell; ICU—intensive care unit; NLR—neutrophil to lymphocyte ratio; PLR—platelet to lymphocyte ratio; MPV—mean platelet volume.